MannKind (MNKD) Redux 10/17/13

And, speaking of MannKind (MNKD)… ***excerpted from Issue #225 of Nate’s Notes (dated 10/11/13)*** Though I have done my best to help keep subscribers focused on the idea that the story at MannKind (or any development stage drug company, for that matter) must be considered “speculative” until the drug being developed has … Continue reading